Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 3.97Zota Health Care Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company maintains strong solvency due to a high equity ratio and no debt, which provides a stable financial foundation. However, liquidity is poor, indicating potential challenges in meeting short-term obligations. Efficiency is also low, with minimal turnover in fixed assets, inventory, and receivables, though the company benefits from high scores in days sales in inventory and receivable days. Growth metrics are weak, except for a high asset growth rate, suggesting significant investments in assets but struggling profitability. Financial ratios are average, with low adjusted EPS but reasonable cash EPS and dividend payouts. Profitability metrics are generally poor, reflecting low returns on capital, equity, and assets. While the asset growth is a positive sign, the company needs to improve its profitability and efficiency to ensure long-term financial health.
Health Score : 3.97Zota Health Care Ltd, operating in the Healthcare Services sector, shows a mixed financial performance. The company maintains strong solvency due to a high equity ratio and no debt, which provides a stable financial foundation. However, liquidity is poor, indicating potential challenges in meeting short-term obligations. Efficiency is also low, with minimal turnover in fixed assets, inventory, and receivables, though the company benefits from high scores in days sales in inventory and receivable days. Growth metrics are weak, except for a high asset growth rate, suggesting significant investments in assets but struggling profitability. Financial ratios are average, with low adjusted EPS but reasonable cash EPS and dividend payouts. Profitability metrics are generally poor, reflecting low returns on capital, equity, and assets. While the asset growth is a positive sign, the company needs to improve its profitability and efficiency to ensure long-term financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
127.56
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
-48.15
P/B RATIO
5.14
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
6.58
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
194.68
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1028.1 as on Sep 1, 2026.
Growth Score : 2.80The company's growth ratios show a mixed performance. While asset growth is strong, indicating significant investments, revenue, operating profit, EPS, and net income growth are low. This suggests that the company is investing in assets without generating corresponding revenue or profit increases. This assessment is based on a weighted average calculation, emphasizing recent performance.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 23.58 | 6.11 | 29.5 | 62.22 | 84.59 |
| Operating Profit Growth Rate | 1400 | -53.33 | 14.29 | -175 | 416.67 |
| Earnings Per Share (EPS) Growth | 4033.33 | -164.69 | -142.36 | -254.95 | -8.38 |
| Asset Growth Rate | 63.53 | 13.67 | 44.3 | 92.54 | 157.63 |
| Net Income Growth Rate | -166.67 | -133.33 | -307.14 | -29.82 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | Morepen Laboratories Ltd | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 11 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 12 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 14 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 17 | Indoco Remedies Ltd | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 22 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Zota Health Care Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations and nutraceuticals. Established in 2000, the company focuses on providing affordable healthcare products across various therapeutic segments, including anti-infectives and pain management, with a growing domestic and international presence.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Zota Health Care Ltd's P/E ratio (TTM) is 127.56, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Zota Health Care Ltd's P/B ratio is 5.14, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Zota Health Care Ltd's P/S ratio is 6.58, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Zota Health Care Ltd's PEG ratio is 1.05.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Zota Health Care Ltd's EV/EBITDA ratio is 194.68.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Zota Health Care Ltd's ROE is -10.66%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Zota Health Care Ltd's ROA is 1.68%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Zota Health Care Ltd's ROCE is -8%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Zota Health Care Ltd's operating margin is 3.53%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Zota Health Care Ltd's net margin is -13.73%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Zota Health Care Ltd's current ratio is 2.56.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Zota Health Care Ltd's debt-to-equity ratio is 0.35.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Zota Health Care Ltd's interest coverage ratio is -3.71.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Zota Health Care Ltd's DPS is ₹1.07.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Zota Health Care Ltd's EPS is -8.38.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1028.10. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2000 (as Zota Health Care Private Limited)
Headquarters: Surat, Gujarat
Core Offerings: Pharmaceutical Formulations (tablets, capsules, injections, syrups), Nutraceuticals, Ayurvedic Products, Over-The-Counter (OTC) products
Stock Listing: NSE (ZOTA), BSE ({bse})
Promoter: Zota Group / Zota Family (led by Ketankumar Zota)
Zota Health Care Ltd was incorporated as Zota Health Care Private Limited in 2000. It converted into a Public Limited Company in 2009. The company was listed on the NSE Emerge platform in 2017 and subsequently migrated to the main board of the National Stock Exchange (NSE) in 2020. Since its inception, Zota Health Care has focused on expanding its product portfolio and market reach both domestically and internationally.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Formulations & Nutraceuticals | 100% | N/A - Company operates as a single primary segment for reporting purposes. |
Pharmaceutical Formulations: Manufactures and markets a wide array of prescription drugs, including tablets, capsules, injections, and syrups, catering to therapeutic areas like anti-infectives, pain management, gastrointestinal, and cardiac care.
Nutraceuticals & OTC Products: Offers a range of dietary supplements, vitamins, minerals, and over-the-counter products focused on general wellness and health maintenance.
Ayurvedic Products: Engaged in the development and distribution of traditional Indian medicine formulations, leveraging ancient herbal remedies for health benefits.
Ketankumar Zota: Chairman & Managing Director. With over two decades of experience, he has been instrumental in the company's growth, strategic direction, and market expansion. Moxesh Zota: Joint Managing Director. He significantly contributes to the company's operational excellence, marketing initiatives, and business development strategies.
Zota Pharmaceuticals Private Limited
Zota Healthcare Inc (USA)
Bonus Issue: 1:1 in November 2023.
The Zota Health Care Ltd share price today is ₹1028.10 on NSE (ZOTA), as of 26 Sept 2026.
As of 25 Sept 2026, Zota Health Care Ltd share price is ₹1028.10, with previous close ₹1028.10. Today's range is ₹1028.10 to ₹1028.10. The 52-week range is ₹1026.20 to ₹1714.70.
As of today, Zota Health Care Ltd's market cap is ₹3,546.94 crore (Small Cap).
Zota Health Care Ltd's current P/E ratio is 127.56, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.
Zota Health Care Ltd's current P/B ratio is 5.14.
Zota Health Care Ltd's current dividend yield is 0.10%. Last dividend of ₹0.50 per share was declared on 07-Sep-2023.
Zota Health Care Ltd's EPS (TTM) is ₹-8.38.
Zota Health Care Ltd is an Indian pharmaceutical company primarily engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations and nutraceuticals. Established in 2000, the company focuses on providing affordable healthcare products across various therapeutic segments, including anti-infectives and pain management, with a growing domestic and international presence.
Zota Health Care Ltd is promoted by Zota Group / Zota Family (led by Ketankumar Zota), holding 49.38% as of 25 Sept 2026.
Zota Health Care Ltd is listed on NSE (ZOTA) and BSE ({bse}). Its next quarterly results are expected on August 2024 (expected for Q1 FY25 results).
